Andexanet Alfa Use in Patients Requiring Cardiopulmonary Bypass: Quo Vadis?

Affiliations

Comment

Jerrold H Levy et al. A A Pract. 2019.

. 2019 Dec 15;13(12):477.

doi: 10.1213/XAA.0000000000001115.

¹ Anesthesiology and Critical Care, Duke University School of Medicine, Durham, North Carolina, jerrold.levy@duke.edu.

No abstract available

Comment on

Andexanet Alfa for Urgent Reversal of Apixaban Before Aortic Surgery Requiring Cardiopulmonary Bypass: A Case Report.
Flaherty D, Connors JM, Singh S, Sylvester KW, Rimsans J, Cornella L. Flaherty D, et al. A A Pract. 2019 Oct 1;13(7):271-273. doi: 10.1213/XAA.0000000000001052. A A Pract. 2019. PMID: 31265446

1. Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol. 2018;15:273–281.
1. Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI; Subcommittee on Control of Anticoagulation. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14:623–627.
1. Flaherty D, Connors JM, Singh S, Sylvester KW, Rimsans J, Cornella L. Andexanet alfa for urgent reversal of apixaban before aortic surgery requiring cardiopulmonary bypass: a case report. A A Pract. 2019;13:271–273.
1. Connolly SJ, Crowther M, Eikelboom JW, et al.; ANNEXA-4 Investigators. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380:1326–1335.